Mucosal Delivery Strategies for Cancer Vaccines

本研究的目标是开发新的粘膜疫苗接种平台，以提高疫苗的疗效 治疗性癌症疫苗。虽然最近的研究表明有限的抗肿瘤反应导致 通过标准的皮下注射癌症疫苗，抗肿瘤效果可能会大幅提高 疫苗投放是否针对特定部位和/或直接针对患病组织。无数的癌症，例如肺癌， 结直肠癌、宫颈癌和Gl癌发生在共同粘膜免疫系统(CMIS)提供服务的组织中。 粘膜免疫反应的激活可能会导致对此类癌症的更大效应功能。另外， 由于粘膜免疫提供了系统免疫，因此粘膜疫苗接种有可能使所有 癌症。系统地研究和开发黏膜疫苗接种平台可能会提高疫苗的疗效 治疗性癌症疫苗。在这项研究中，将开发五个靶向粘膜淋巴组织的平台 经口腔、经鼻、经阴道、经直肠和经肺组织。除了突出的 免疫疗法的好处，量身定做的黏膜疫苗接种将促进更多的理解 粘膜免疫对预防癌症以及其他感染或病理有潜在影响。

The goal of this research is to develop novel mucosal vaccination platforms to improve the efficacy of therapeutic cancer vaccines. While recent research has demonstrated limited antitumor responses resulting from standard subcutaneous injections of cancer vaccines, antitumor efficacy may be substantially improved if vaccine delivery is site-specific and/or targeted directly to diseased tissues. Numerous cancers, e.g. lung, colorectal, cervical and Gl cancers, arise in tissues served by the common mucosal immune system (CMIS). Activation of a mucosal immune response may lead to a greater effector function against such cancers. Also, since mucosal immunity confers systemic immunity, mucosal vaccination has the potential to reach all cancers. A systematic study and development of mucosal vaccination platforms may enhance the efficacy of therapeutic cancer vaccines. In this study, five platforms will be developed to target mucosal lymphoid tissues via oral, intranasal, intravaginal, intrarectal and intrapulmonary routes. In addition to the salient benefits of immunotherapy, tailored mucosal administrations of vaccines will foster a greater understanding of mucosal immunity potentially impacting prophylaxes of cancers as well as other infections or pathologies.